BioCryst Pharmaceuticals BCRX Restricted stock acquisition consideration
Restricted stock acquisition consideration at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's restricted stock acquisition consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's restricted stock acquisition consideration?
- BioCryst Pharmaceuticals (BCRX) reported restricted stock acquisition consideration of $0 in Q1 2026.
- What does restricted stock acquisition consideration mean?
- Represents the total value of restricted stock units or awards granted to employees and directors as part of compensation packages. This metric reflects the company's use of equity-based incentives to align the interests of key personnel with long-term shareholder value.